InvestorsHub Logo
Followers 0
Posts 68
Boards Moderated 0
Alias Born 01/28/2014

Re: ALL IN2 post# 2806

Wednesday, 10/08/2014 10:53:06 AM

Wednesday, October 08, 2014 10:53:06 AM

Post# of 5918
NICE says it is not cost effective. When the UK government won't cover or subsidize the cost of Sativex, then MS sufferers can't afford it. That translates into a lot of loss revenue for GW in the UK.

Pure and simple, we need FDA approval in the U.S. to generate revenue. GW can't continue issuing more shares. That's not a viable strategy.